New hope for multiple myeloma patients with no options left
NCT ID NCT05757973
Summary
This program provides access to an investigational drug called talquetamab for people with multiple myeloma that has returned or stopped responding to all available treatments. Talquetamab is designed to help the body's own immune T-cells find and attack the cancer cells. It is offered to patients who have run out of standard treatment options and cannot join a clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.